Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Dynavax Technologies Corporation
Dynavax Technologies shares declined nearly 30 percent on more than six times its average daily volume Friday. The company announced that the FDA has stated that their investigational adult hepatitis B vaccine, HEPLISAV, cannot be approved for use in adults 18-70 years of age without further evaluation of safety..
Going forward ... (see research report)
Subscribe to News Feeds